Michael Yan, MD MPH

🇨🇦 |Radiation Oncologist @RadMedPM @PMcancercentre @UofTdro | Alumnus @Sunnybrook @QueensOncology @JohnsHopkinsSPH @SchulichMedDent | Views = mine

[Andrew Moon @AndrewMMoon]

So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO

These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC.

https://t.co/dJI1SdMwnK

[Shankar Siva @_ShankarSiva]

Thank you @TheLancetOncol for accepting the concurrent publication of the data…. To read more see QR code here; #ESTRO26 #radonc

[Michael Chuong @MikeChuongMD]

Ablative RT often causes tissue changes within a few mm outside of the target lesion

Can give the appearance of tumor "growth" when this often is pseudoprogression

CT/MRI reports often do not reflect this possibility

Larger size does not always mean local failure!!

[arjun sahgal @SahgalArjun]

The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence https://t.co/IHALJ97ZCa

[Piet Ost @piet_ost]

1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Wow. Thank you everyone for such an amazing response to this article. 60K views in 24 hrs for an academic article in the current era of X is truly encouraging. Speaks to the “unmet need” of educational resources for critical appraisal. https://t.co/wm7VADhS5k

[Michael Yan, MD MPH @MichaelYanMD]

@CJTsaiMDPhD @isteddos @JAMANetworkOpen @SahgalArjun @CDNCancerTrials @ldawsonmd @naummalik @RebeccaKSWong @WinstonVuong @piet_ost Saw the same with a sc24 and spine mets no difference in VCF when using 2F SBRT

[Joshua D. Palmer, MD @joshuapalmermd]

Check out our amazing meta analysis FIRE-STORM, showing PFS significantly better with DE-RT over 66 Gy in 33 for high grade meningioma. We hope this will help as we prepare to show for over 70 Gy improves control in future trial!!

https://t.co/ji3h0jv2jB

[Mark Yarchoan @MarkYarchoan]

Barcelona HCC classification may not reflect current treatment practices in US
The new BEACON-HCC Classification was introduced for comment today @HCCLIVEConf - pls weigh in!
Pilot real-world cases: Expert concordance 100% with BEACON-HCC vs 58.6% with 2022 #BCLC

[Aisling Barry @aislingbarryro]

#HRQOL #oligoprog #SBRT
🔥RADIANT - phII oligoprog GI, GU, breast
🔵 secondary outcome - HRQOL
⬇️ mean global health SS but not clinically significant at 6m

🔵disease progression predictor of worse HRQOL on MVA
🔵if no prog HRQOL was stable or improved in 83%

1/

[Jane Jomy @JaneJomy]

𖠣 New in @TheJNS Spine: Does timing matter? Analysis led by @MichaelYanMD @UHN found improved locoregional cancer control among patients who receive radiotherapy before vertebral augmentation for spine metastases: https://t.co/Az8n6ItwyD @UofTDRO @UofTNeuroSurge @UofTMedIm

[CL Chiang @clchiang_hk]

First prospective series to demonstrate #SBRT could induce contralateral lobe hypertrophy in #HCC

- Around 30% increase in FLR
- Fastest rate in first 3 months
- Ongoing hypertrophy until plateauing at 12 months

Full text link: https://t.co/INlpGlX0ay

[Laura Dawson @ldawsonmd]

Excellent outcomes from HK following SBRT-IO for HCC (73% MVI, med. 11cm).

Strong rationale for phase 3 RCTs. Please support #NRG GI012 IO+\- SBRT for HCC w MVI.

[Dr. Nina Niu Sanford @NiuSanford]

Long-term results of Ph2 celiac plexus SRS trial (n=107)

1 dose RT (25Gy) led to 60% pain reduction & pain control for 4+ mo.

Suggestion of better durability when tumor included (w plexus) in RT volume.

RCT in development. Great work Yaacov Lawrence & team! #GI26 @OncoAlert

[Michael Yan, MD MPH @MichaelYanMD]

@NiuSanford SOCRATES trial ongoing, hoping to open locally soon @TROGfightcancer @DavePryorRO

[Dr. Nina Niu Sanford @NiuSanford]

Advanced cirrhosis (CP-B8/C) often precludes embolic bridging (Y90/TACE) in HCC, so options limited.

Small, uniquely targeted pilot study suggests SBRT could fill gap: local control 100% (40Gy/5fx), & 67% transplanted or eligible after 1 yr. @OncoAlert

https://t.co/gWepOHJLoV

[Michael Yan, MD MPH @MichaelYanMD]

@SprakerMDPhD They fixed it this year thanks to the tremendous effort put forth by @tedradonc

https://t.co/5Rzwvv7dHU

[Michael Yan, MD MPH @MichaelYanMD]

Absolute pleasure hosting @lauren_henke @APrice_BeamOn and learning from world leaders in adaptive RT. Innovative as always, and inspiration to leverage tech to move the needle and improve patient outcomes.

[Lauren Henke, MD, MSCI @lauren_henke]

Wonderful to get to visit friends @RadMedPM 🇨🇦 + rep @RadOncUH w/ @APrice_BeamOn 💪🏼Hard to beat company like @ldawsonmd @j_lukovic @MichaelYanMD et al, getting to be part of their annual GI SBRT course, & even getting to talk about pancreas RT on World Pancreatic Cancer Day 💜 Thanks for having us! @caseccc @UH_RE_Institute

[Jane Jomy @JaneJomy]

Our meta-analysis on the impact of biologically effective dose and dose-rate in #GammaKnife radiosurgery in trigeminal neuralgia is in @Advances_ASTRO! @MichaelYanMD @detsang @UofTDRO

[Garrett Green, MD @ggreen1986]

Psuedoprogression Radiation Necrosis vs progression new imaging techniques treating Rad Nec using Boswellia CNS PRO session #ASTRO25